Literature DB >> 10628323

Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation.

M L Caruso1, A M Valentini.   

Abstract

p53 mutant protein has been found in a variety of human malignancies. In order to assess the controversial role of p53 protein in hepatocellular carcinoma (HCC) we studied its immunohistochemical expression in a series of 193 HCC specimens. Positive immunostaining for p53 was detected in the nuclei of neoplastic cells of 29 (15%) HCCs. There was no immunohistochemical evidence of mutant p53 expression either in normal or cirrhotic tissue surrounding neoplastic tissue. Higher alphafetoprotein serum levels were significantly associated with p53 overexpression. A prevalence of p53+ HCC specimens was seen in HCV negative patients (36% vs 13%, p < 0.05). No statistically significant correlations between p53 overexpression, age, sex, and HBV infection status were found. As regards histological grading, p53 was detected more frequently in tumours with poor cellular differentiation, although this finding does not reach statistical significance. The p53+ HCC rate was comparable to that attributed to the low incidence areas for HCC, in epidemiological studies. Moreover, p53 mutation seems to be related to the reactivation of alphafetoprotein gene to a more aggressive phenotype and to a later stage of liver carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10628323

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Hyperthermia inhibits recombination repair of gemcitabine-stalled replication forks.

Authors:  Mustafa Raoof; Cihui Zhu; Brandon T Cisneros; Heping Liu; Stuart J Corr; Lon J Wilson; Steven A Curley
Journal:  J Natl Cancer Inst       Date:  2014-08-15       Impact factor: 13.506

Review 2.  LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential.

Authors:  Christopher S Hong; Winson Ho; Chao Zhang; Chunzhang Yang; J Bradley Elder; Zhengping Zhuang
Journal:  Cancer Biol Ther       Date:  2015-04-21       Impact factor: 4.742

3.  Heat shock protein 70 chaperoned alpha-fetoprotein in human hepatocellular carcinoma cell line BEL-7402.

Authors:  Xiao-Ping Wang; Qiao-Xia Wang; Hai-Yan Li; Rui-Fen Chen
Journal:  World J Gastroenterol       Date:  2005-09-21       Impact factor: 5.742

4.  Gene expression patterns in human liver cancers.

Authors:  Xin Chen; Siu Tim Cheung; Samuel So; Sheung Tat Fan; Christopher Barry; John Higgins; Kin-Man Lai; Jiafu Ji; Sandrine Dudoit; Irene O L Ng; Matt Van De Rijn; David Botstein; Patrick O Brown
Journal:  Mol Biol Cell       Date:  2002-06       Impact factor: 4.138

5.  Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells.

Authors:  Meng-Sen Li; Ping-Feng Li; Qian Chen; Guo-Guang Du; Gang Li
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

6.  TOP2A amplification and overexpression in hepatocellular carcinoma tissues.

Authors:  Ravat Panvichian; Anchalee Tantiwetrueangdet; Napat Angkathunyakul; Surasak Leelaudomlipi
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

7.  Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study.

Authors:  Wei He; Yun Zheng; Ruhai Zou; Jingxian Shen; Junping Yang; Jiliang Qiu; Qiang Tao; Wenwu Liu; Zhiwen Yang; Yuanping Zhang; Binkui Li; Yunfei Yuan
Journal:  Cancer Commun (Lond)       Date:  2018-05-21

Review 8.  Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.

Authors:  So Young Yoo; Narayanasamy Badrinath; Hyun Young Woo; Jeong Heo
Journal:  Mediators Inflamm       Date:  2017-04-20       Impact factor: 4.711

Review 9.  Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

Authors:  Jennifer Eatrides; Emilie Wang; Nishi Kothari; Richard Kim
Journal:  Cancer Control       Date:  2017 Jul-Sep       Impact factor: 3.302

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.